Does Premera Blue Cross Cover GLP-1
Medications? 2026 Guide

Premera Blue Cross is Washington state's largest commercial insurer, covering hundreds of thousands of residents through employer-sponsored plans and individual policies. If you're a Premera member asking whether your plan covers GLP-1 medications like Ozempic, Wegovy, Mounjaro, or Zepbound, the answer is complicated — and depends heavily on your specific indication and whether your employer opted into anti-obesity medication coverage.

At Revive, we work with Premera members navigating GLP-1 coverage regularly. This guide covers exactly what's covered under which conditions, how prior authorization works, and what alternative coverage pathways may apply — including the cardiovascular risk reduction pathway that can unlock coverage even without an AOM rider.

Premera's GLP-1 Coverage by Indication

Premera's coverage for GLP-1 receptor agonists is governed by separate clinical policies depending on indication. The same drug can be covered under one indication and excluded under another. Understanding which policy applies to your situation is the first step.

The AOM Rider: Why Most Premera Members Don't Have GLP-1 Weight Loss Coverage

The most important thing Premera members need to understand is that GLP-1 coverage for weight management is not a standard benefit — it requires employers to opt into what's called an anti-obesity medication (AOM) rider. Employer groups pay an additional premium to add this rider to their plan. Many employers have declined to add it, citing cost.

Premera's Policy 5.01.621 — which governs weight management drug coverage — only applies if your employer's plan includes the AOM rider. Without it, Wegovy and Zepbound for obesity are excluded entirely regardless of medical necessity, BMI, or comorbidities. Industry estimates suggest roughly 40–50% of commercial Washington plans include some GLP-1 obesity coverage, though the AOM rider penetration varies significantly by employer size.

Prior Authorization Requirements

As of January 2025, Premera requires prior authorization for all GLP-1 receptor agonists — including Ozempic, which previously did not require PA on all plans. The specific criteria vary by indication:

• PA required for ALL GLP-1s since January 2025, including Ozempic.
• For Type 2 Diabetes: HbA1c ≥7%, confirmed T2D diagnosis in the medical record, metformin trial documented (or documented contraindication).
• For obesity (when AOM rider present): BMI documentation, 3–6 months of lifestyle modification documented, prior weight loss medication history if applicable.
• Ozempic dose must be documented at ≤2 mg/week — doses above this threshold may be flagged as Wegovy territory and trigger a separate review under the weight management policy rather than the diabetes policy.
• For CV risk reduction: Document established cardiovascular disease and BMI ≥27 using appropriate cardiovascular ICD-10 codes (I25.x for coronary artery disease, I63.x for stroke, I70.x for peripheral arterial disease).

The CV Risk Pathway: Covered Even Without an AOM Rider

This is one of the most important and underutilized coverage pathways for Premera members. In March 2024, the FDA approved Wegovy (semaglutide) specifically for cardiovascular risk reduction in patients with established cardiovascular disease and a BMI of 27 or higher — separate from its weight management indication.

Premera treats this as a distinct clinical indication, governed separately from Policy 5.01.621 (weight management). This matters because the AOM rider restriction applies to weight management drugs — not to cardiovascular medications. For patients with a prior heart attack, stroke, or peripheral arterial disease plus a BMI ≥27, Wegovy for CV risk reduction may be approvable on plans that would otherwise exclude it for obesity.

The critical factor is documentation: the PA submission must use cardiovascular ICD-10 codes (I25.x, I63.x, I70.x) and frame the clinical narrative around established CVD — not weight loss. The clinical rationale and the codes you submit determine which Premera policy applies.

Estimated Patient Costs

When GLP-1 coverage is active on your Premera plan, these are typical out-of-pocket costs after your deductible is met. Actual costs depend on your specific plan's specialty tier structure and deductible status.

Why the Clinical Documentation You Submit Matters

Premera's coverage decision on your GLP-1 PA is driven almost entirely by the ICD-10 codes and clinical narrative in the submitted documentation. Two patients on the same drug, at the same dose, with similar BMIs can receive completely different coverage outcomes based on how their prior authorization is framed.

A patient with Type 2 diabetes submitting under the diabetes policy (5.01.569) with HbA1c ≥7% and a documented metformin trial has a clear, well-defined path to approval. A patient with established coronary artery disease submitting under cardiovascular ICD-10 codes has a different but equally valid path. A patient submitting purely for weight management without an AOM rider has no path regardless of medical need.

Having a provider who understands Premera's specific policies, which indication applies to your situation, and how to frame the clinical narrative accordingly is the difference between approval and denial.

Why Revive for Premera GLP-1 Patients

• Comprehensive lab panel: Our first-visit labs include HbA1c, lipid panel, complete metabolic panel, and CBC — satisfying the documentation requirements for Premera's T2D and CV risk PA criteria from the very first visit.
• FDA-approved medications to retail pharmacies: We prescribe FDA-approved GLP-1 medications to standard retail pharmacies (Walgreens, Costco, CVS) — fully compatible with your Premera pharmacy benefit.
• PA management team: We handle Premera prior authorization submission, follow-up, and appeals — including identifying which indication pathway maximizes your approval chances.
• Integrated TRT + GLP-1 care: For men managing both low testosterone and metabolic health, we provide coordinated care under one clinical team — labs, prescriptions, and monitoring all in one place.

Common Questions

Does Premera cover Ozempic for weight loss?

Ozempic is FDA-approved for Type 2 diabetes, not weight management. If you have T2D with HbA1c ≥7% and a documented metformin trial, Ozempic is coverable under Premera's diabetes policy (5.01.569) with PA. If you want Ozempic purely for weight loss, Premera applies the same analysis as Wegovy — it requires the AOM rider, and if your plan doesn't have it, it's excluded.

My Premera plan doesn't cover weight loss GLP-1s. Are there other options?

Yes — three alternative pathways are worth exploring. First, the cardiovascular risk reduction pathway: if you have established CVD (prior MI, stroke, peripheral arterial disease) and BMI ≥27, Wegovy for CV risk may be covered without an AOM rider. Second, the obstructive sleep apnea pathway: if you have a sleep study confirming AHI ≥15 and BMI ≥30, Zepbound for OSA may be approvable. Third, self-pay: Novo Nordisk's NovoCare patient assistance program offers Wegovy at approximately $349/month direct pricing, with an introductory rate of $199 for the first two fills.

How do I know if my Premera plan has an AOM rider?

Call the member services number on the back of your Premera insurance card and ask specifically: "Does my plan include anti-obesity medication coverage?" or "Is Wegovy or Zepbound on my formulary for weight management?" The general benefits line can often confirm this in minutes. You can also log in to your Premera member portal and check your Summary of Benefits document for exclusions.

Related GLP-1 Coverage Guides

• GLP-1 Insurance Coverage in Washington State (Complete Guide)
• Regence GLP-1 Coverage
• Kaiser GLP-1 Coverage
• UnitedHealthcare GLP-1 Coverage
• Aetna GLP-1 Coverage